Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC with toripalimab and chemotherapy or trastuzumab in gastric cancer
NCT05980481Phase 3Active, not recruiting
- Sponsor
- RemeGen
- Start
- Aug 2023
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of disitamab vedotin in gastric cancer (GC), gastroesophageal adenocarcinoma, sponsored by RemeGen. Started Aug 2023; status: active, not recruiting.
02
Drugs
disitamab vedotin
03
Conditions
gastric cancer (GC)gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT05980481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05980481.